TET2 and acute myeloid leukemia: In addition, loss-of-function mutations in TET2 and a resultant reduction in 5-hmC are observed in myeloid malignancies, including acute myeloid leukemia (AML), chronic myelomonocytic leukemia and myelodysplastic syndrome [8, 9].